From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Synonyms Stilbostat
CAS Number
PubChem CID
Chemical and physical data
Formula C28H34Cl4N2O4
Molar mass 604.39256 g/mol
3D model (JSmol)

ICI-85966 (former tentative brand name Stilbostat), also known as diethylstilbestrol (DES) bis(di(2-chloroethyl)carbamate), is a synthetic, nonsteroidal estrogen and alkylating antineoplastic agent of the stilbestrol group and a cytostatic nitrogen mustard ester of diethylstilbestrol (DES) that was developed for the treatment of breast cancer and prostate cancer but was never marketed (possibly due to the toxcitity of DES).[1][2][3][4][5] It was found to markedly improve the clinical state in approximately 65% of women treated with it for advanced breast cancer in a clinical study.[4]

See also[edit]


  1. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 397. ISBN 978-1-4757-2085-3. 
  2. ^ Zimel H, Broder D, Zimel A (1973). "[Therapeutic effects of the preparation "Stilbostat" in advanced stages of breast cancer after the menopause]". Stud Cercet Endocrinol (in Romanian). 24 (3): 211–9. PMID 4703920. 
  3. ^ Görlich M, Heise E (1976). "Contribution to the mechanism of Stilbostat action". Neoplasma. 23 (4): 363–9. PMID 1004653. 
  4. ^ a b Zimel H, Mogos I, Maltezeanu G (1977). "Estimation of StilbostatR treatment efficiency in breast cancer by thermography". Neoplasma. 24 (5): 553–7. PMID 927612. 
  5. ^ Zimel H, Bocancea D (1974). "Treatment of prostatic carcinoma with Stilbostat". Neoplasma. 21 (1): 101–8. PMID 4596007.